Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates

Core Viewpoint - Veracyte reported strong quarterly earnings, exceeding expectations and showing significant year-over-year growth in both earnings and revenues [1][2]. Financial Performance - The company achieved earnings of $0.53 per share, surpassing the Zacks Consensus Estimate of $0.41 per share, and up from $0.36 per share a year ago, representing an earnings surprise of +30.06% [1]. - Revenues for the quarter reached $140.64 million, exceeding the Zacks Consensus Estimate by 1.41% and up from $118.63 million in the same quarter last year [2]. Market Performance - Veracyte shares have declined approximately 15.2% since the beginning of the year, while the S&P 500 has gained 0.7% [3]. - The company's stock is currently rated Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.34, with projected revenues of $131.36 million, and for the current fiscal year, the EPS estimate is $1.61 on revenues of $577.29 million [7]. - The Medical - Instruments industry, to which Veracyte belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8].